1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adagio Therapeutics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Andes

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Ansa Biotechnologies

Antheia

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio (Flagship)

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

ArsenalBio

Artisan Bio

Artiva Biotherapeutics

Aruvant

Ascidian Therapeutics

Ascribe Bioscience

Acrivon Therapeutics is using a proteomics-based approach to develop precision oncology therapeutics. While the underlying basis of cancer is genomic alterations, it is the dysregulated proteome that drives the disease. Proteomic biomarkers therefore offer a more accurate matching of patients with drugs than genomic biomarkers. Acrivon is using their proprietary Predictive Precision Proteomics platform to develop patient selection tumor biopsy tests, called OncoSignature® tests, to identify which patients will benefit from a specific drug, matching drug mechanisms to the biologic drivers of cancer. Acrivon’s clinical pipeline is currently focused on advanced assets targeting the DNA damage response where traditional patient selection is challenging, with Phase 2 trials initiated.

<p>Acrivon Therapeutics is using a proteomics-based approach to develop precision oncology therapeutics. While the underlying basis of cancer is genomic alterations, it is the dysregulated proteome that drives the disease. Proteomic biomarkers therefore offer a more accurate matching of patients with drugs than genomic biomarkers. Acrivon is using their proprietary Predictive Precision Proteomics platform to develop patient selection tumor biopsy tests, called OncoSignature® tests, to identify which patients will benefit from a specific drug, matching drug mechanisms to the biologic drivers of cancer. Acrivon’s clinical pipeline is currently focused on advanced assets targeting the DNA damage response where traditional patient selection is challenging, with Phase 2 trials initiated.</p>


Find a biotech startup job.